SCN9A has been proposed suggested as a genetic modifier in SCN1A mutation linked with GEFS+ and as a potential susceptibility gene for Dravet syndrome [6, 7]. This evidence concerns the gene SCN9A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.